NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly earnings results on February 18, 2026 that fell short of analyst expectations. The Healthcare company reported earnings per…
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly earnings results on February 18, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.63, missing the consensus estimate of $-0.38 by $0.25 per share. Revenue came in at $32.0K, missing the estimate of $4.3M.
NewAmsterdam Pharma's stock moved following the earnings release. The stock currently trades at $34.30 with a market capitalization of $4.1B.
Current market data
NASDAQ · NAMS
$25.40
Down: -$0.67 · -2.64%
Live quote updated
Our Markets Team monitors market data, SEC filings, analyst actions, earnings releases, and corporate announcements to produce timely updates for investors.
Keep reading
sec_filing ·
sec_filing ·
price ·
sec_filing ·
